Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the children's oncology group Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Bone Neoplasms
  • Ifosfamide
  • Osteosarcoma

abstract

  • The addition of ifosfamide to cisplatin, doxorubicin, and methotrexate did not enhance EFS or overall survival for patients with osteosarcoma. The addition of MTP to chemotherapy resulted in a statistically significant improvement in overall survival and a trend toward better EFS.

publication date

  • February 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.14.0095

PubMed ID

  • 18235123

Additional Document Info

start page

  • 633

end page

  • 8

volume

  • 26

number

  • 4